GlassScriptPhysician profile
James R Ford
NPI 1346867561
$2,523.00
in general payments reported to CMS, 2019-2025
30 companies · $647 in 2025
The $647 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $636 · 2023: $536 · 2024: $541 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.05 | 2021-2025 | |
| Lilly USA, LLC | $226.19 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $184.75 | 2022-2025 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $176.71 | 2022-2025 | Embold Fibered, Wavewriter Alpha Prime 16 |
| Pfizer INC. | $164.37 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.86 | 2022 | |
| Tris Pharma INC | $132.78 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $82.67 | 2022-2025 | Qelbree, Qelbree |
| Organon LLC | $73.58 | 2023-2025 | Nexplanon |
| Corcept Therapeutics | $70.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $66.01 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $60.78 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Corium, LLC | $56.77 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $56.43 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.78 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $38.71 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $34.92 | 2023-2024 | Arexvy, Shingrix |
| Cranial Technologies, INC | $33.96 | 2022-2023 | Doc Band |
| Sanofi-Aventis U.S. LLC | $33.75 | 2022 | |
| Vanda Pharmaceuticals INC. | $31.04 | 2024 | Fanapt |
| Axsome Therapeutics, INC. | $26.23 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $24.97 | 2024 | Keveyis |
| Novartis Pharmaceuticals Corporation | $23.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.88 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.59 | 2022 | |
| Apria Healthcare LLC | $15.29 | 2021 | |
| Exact Sciences Corporation | $15.04 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.04 | 2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $14.54 | 2021 | |
| Seqirus USA INC | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.